Australian accelerator launched this week to fast‑track neurotechnology firms, pairing startup builder Founders Factory with the Multiple Sclerosis Welfare Association (MSWA). The joint venture will channel venture‑capital funds into early‑stage companies for the first time, a move driven by MSWA chief executive Melanie Kiely. Investors hope the program will bridge a funding gap in treatments for multiple sclerosis and related disorders. It also provides mentorship from leading clinicians.

Five startups from the United States and Europe earned spots in the inaugural cohort, targeting stroke‑risk assessment, mobility enhancement and other neurological endpoints. Their selection underscores growing investor appetite for digital health tools that promise measurable clinical outcomes. By aggregating diverse expertise, the accelerator aims to create a pipeline that can attract follow‑on financing from larger biotech funds.

Backers expect the program to accelerate commercialization, shortening the path from prototype to market and potentially delivering therapies to patients faster. Success will be measured by the amount of capital raised in subsequent rounds and regulatory milestones achieved by cohort companies. The accelerator now stands as a new conduit for venture money into the neurotech sector.